146 related articles for article (PubMed ID: 31965718)
1. The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion transcript.
Brunac AC; Laprie A; Castex MP; Laurent C; Le Loarer F; Karanian M; Le Guellec S; Guillemot D; Pierron G; Gomez-Brouchet A
Pediatr Blood Cancer; 2020 May; 67(5):e28185. PubMed ID: 31965718
[No Abstract] [Full Text] [Related]
2. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases.
Xu B; Suurmeijer AJH; Agaram NP; Zhang L; Antonescu CR
Histopathology; 2021 Sep; 79(3):347-357. PubMed ID: 33382123
[TBL] [Abstract][Full Text] [Related]
3. Spindle cell rhabdomyosarcoma in a lumbar vertebra with FUS-TFCP2 fusion.
Tagami Y; Sugita S; Kubo T; Iesato N; Emori M; Takada K; Tsujiwaki M; Segawa K; Sugawara T; Kikuchi T; Hasegawa T
Pathol Res Pract; 2019 Aug; 215(8):152399. PubMed ID: 30948206
[TBL] [Abstract][Full Text] [Related]
4. Lack of clinical activity with crizotinib in a patient with FUS rearranged rhabdomyosarcoma with ALK protein overexpression.
Lewin J; Desai J; Smith K; Luen S; Wong D
Pathology; 2019 Oct; 51(6):655-657. PubMed ID: 31470995
[No Abstract] [Full Text] [Related]
5. Rhabdomyosarcoma With
Zhong P; Wei S; Xiao H; Zeng Y
Int J Surg Pathol; 2024 Jun; 32(4):758-766. PubMed ID: 37545350
[TBL] [Abstract][Full Text] [Related]
6. Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two cases.
Chrisinger JSA; Wehrli B; Dickson BC; Fasih S; Hirbe AC; Shultz DB; Zadeh G; Gupta AA; Demicco EG
Virchows Arch; 2020 Nov; 477(5):725-732. PubMed ID: 32556562
[TBL] [Abstract][Full Text] [Related]
7. Spindle cell rhabdomyosarcoma of bone with FUS-TFCP2 fusion: confirmation of a very recently described rhabdomyosarcoma subtype.
Dashti NK; Wehrs RN; Thomas BC; Nair A; Davila J; Buckner JC; Martinez AP; Sukov WR; Halling KC; Howe BM; Folpe AL
Histopathology; 2018 Sep; 73(3):514-520. PubMed ID: 29758589
[TBL] [Abstract][Full Text] [Related]
8. Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype.
Agaram NP; Zhang L; Sung YS; Cavalcanti MS; Torrence D; Wexler L; Francis G; Sommerville S; Swanson D; Dickson BC; Suurmeijer AJH; Williamson R; Antonescu CR
Am J Surg Pathol; 2019 May; 43(5):695-702. PubMed ID: 30720533
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous rhabdomyosarcoma with FUS::TFCP2 fusion: A case report emphasizing early detection.
Demirkesen C; Danyeli AE; Yıldız P; Ertekin SS; Yılmaz B; Karahan Sİ; Bahrami A
J Cutan Pathol; 2023 Dec; 50(12):1059-1064. PubMed ID: 37669767
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition.
Kim D; Koh Y; Yoon SS
Anticancer Res; 2020 Mar; 40(3):1395-1403. PubMed ID: 32132036
[TBL] [Abstract][Full Text] [Related]
11. Complete mimicry: Rhabdomyosarcoma with FUS::TFCP2 fusion masquerading as carcinoma-diagnostic challenge and report of two cases.
Carrillo-Ng H; Liang Y; Chang S; Afkhami M; Gernon T; Bell D; Arias-Stella JA
Genes Chromosomes Cancer; 2023 Jul; 62(7):430-436. PubMed ID: 37057803
[TBL] [Abstract][Full Text] [Related]
12. Alectinib shows CNS efficacy in ALK-positive NSCLC.
Gourd E
Lancet Oncol; 2018 Oct; 19(10):e520. PubMed ID: 30245054
[No Abstract] [Full Text] [Related]
13. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
[TBL] [Abstract][Full Text] [Related]
14. Two cases of marked red cell anisopoikilocytosis and haemolysis with alectinib, an anaplastic lymphoma kinase inhibitor.
Yuan Y; Mapp S; Xu W
Br J Haematol; 2020 Sep; 190(5):642. PubMed ID: 32537738
[No Abstract] [Full Text] [Related]
15. Clinicopathological features of rhabdomyosarcoma with novel FET::TFCP2 and TIMP3::ALK fusion: report of two cases and literature review.
Duan FL; Yang H; Gong X; Zuo Z; Qin S; Ji J; Zhou C; Dai J; Guo P; Liu Y
Histopathology; 2023 Feb; 82(3):478-484. PubMed ID: 36350070
[TBL] [Abstract][Full Text] [Related]
16. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines.
Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S
Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib.
Tomlinson SB; Sandwell S; Chuang ST; Johnson MD; Vates GE; Reagan PM
Leuk Res; 2019 Aug; 83():106164. PubMed ID: 31226541
[No Abstract] [Full Text] [Related]
18. Rhabdomyosarcoma With
Ishiyama T; Kato I; Ito J; Matsumura M; Saito K; Kawabata Y; Kato S; Takeyama M; Fujii S
Int J Surg Pathol; 2023 Aug; 31(5):805-812. PubMed ID: 36437645
[TBL] [Abstract][Full Text] [Related]
19. Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung.
Balzer BWR; Loo C; Wegner EA; Nath CE; Lee S; Smith C; Lewis CR; Trahair TN; Anazodo AC
Pediatr Hematol Oncol; 2018; 35(7-8):415-421. PubMed ID: 30526220
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and Molecular Characteristics of Intraosseous Rhabdomyosarcoma Involving Head and Neck Region: A Systematic Review and Meta-Analysis.
Sivakumar N; Sharma P; Chandra S; Gupta S; Samadi FM; Baghel S
Pediatr Dev Pathol; 2023; 26(3):299-309. PubMed ID: 37082926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
